gms | German Medical Science

German Congress of Orthopedic and Trauma Surgery (DKOU 2017)

24.10. - 27.10.2017, Berlin

CCL-2 as possible early marker for remission after traumatic spinal cord injury

Meeting Abstract

  • presenting/speaker Raban Heller - Heidelberg Trauma Research Group, Universität Heidelberg, Heidelberg, Germany
  • Bahram Biglari - BG-Klinik Ludwigshafen, Uni-Heidelberg, Querschnittgelähmte u. tech.Othropädie, Ludwigshafen, Germany
  • Volker Daniel - Institut für Transplantationsimmunologie, Heidelberg, Germany
  • Arash Moghaddam-Alvandi - Klinikum Aschaffenburg-Alzenau, Zentrum für Unfallchirurgie, Orthopädie und Sportmedizin, Aschaffenburg, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2017). Berlin, 24.-27.10.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocPO11-1239

doi: 10.3205/17dkou602, urn:nbn:de:0183-17dkou6020

Published: October 23, 2017

© 2017 Heller et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objectives: Subsequent to traumatic spinal cord injuries (TSCI) the associated various pathophysiological processes are still poorly understood. In this study we sought to determine the mechanisms of chemotaxis as an integral part of the neuroinflammatory processes after TSCI.

Methods: Samples and clinical data of 141 patients affected by a TSCI were collected. We examined the serum levels of CCL-2, CCL-3, CCL-4 and CXCL-5 over a 12-week period; in particular., at admission and 4, 9, 12 hours, 1 and 3 days and 1, 2, 4, 8, 12 weeks after trauma. According to our study design, we matched 10 patients with TSCI and neurological remission with 10 patients with an initial ASIA A grade and no neurological remission. Ten patients with vertebral fracture without neurological deficits served as control. Our analysis was performed using a Luminex Cytokine Panel. Multivariate logistic regression models were used to examine the predictive value with respect to neurological remission vs. no neurological remission.

Results and Conclusion: The results of our study showed differences in the serum expression patterns of CCL-2 in association with the neurological remission (CCL-2 at admission p=0.013). Serum levels of CCL-2 and CCL-4 were significantly different in patients with and without neurological remission. The favoured predictive model resulted in an AUC of 93.1% in the ROC analysis.

Our results indicate that peripheral serum analysis is a suitable concept for predicting the patient's potential for neurological remission after TSCI. Furthermore, the initial CCL-2 concentration provides an additional predictive value compared to the NLI (neurological level of injury). Therefore the present study introduces a promising approach for future monitoring concepts and tracking techniques for current therapies. The results indicate that future investigations with an enlarged sample size are needed in order to develop monitoring, prognostic and scoring systems.